<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37034660</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2023.03.30.23287923</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2023.03.30.23287923</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The associations between longitudinal dynamics and the breadth of SARS-CoV-2 neutralizing antibody response with various Long COVID (LC) phenotypes prior to vaccination are not known. The capacity of antibodies to cross neutralize a variety of viral variants may be associated with ongoing pathology and persistent symptoms.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We measured longitudinal neutralizing and cross-neutralizing antibody responses to pre- and post-SARS-CoV-2 Omicron variants in participants infected during the early waves of the COVID-19 pandemic, prior to wide-spread rollout of SARS-CoV-2 vaccines. Cross sectional regression models adjusted for various clinical covariates and longitudinal mixed effects models were used to determine the impact of the breadth and rate of decay of neutralizing responses on the development of Long COVID symptoms in general, as well as LC phenotypes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We identified several novel relationships between SARS-CoV-2 antibody neutralization and the presence of LC symptoms. Specifically, we show that, although neutralizing antibody responses to the original, infecting strain of SARS-CoV-2 were not associated with LC in cross-sectional analyses, cross-neutralization ID50 levels to the Omicron BA.5 variant approximately 4 months following acute infection was independently and significantly associated with greater odds of LC and with persistent gastrointestinal and neurological symptoms. Longitudinal modeling demonstrated significant associations in the overall levels and rates of decay of neutralization capacity with LC phenotypes. A higher proportion of participants had antibodies capable of neutralizing Omicron BA.5 compared with BA.1 or XBB.1.5 variants.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Our findings suggest that relationships between various immune responses and LC are likely complex but may involve the breadth of antibody neutralization responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buck</LastName><ForeName>Amanda M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deitchman</LastName><ForeName>Amelia N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Saki</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Sarah A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Meghann C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerbleski</LastName><ForeName>Marian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deveau</LastName><ForeName>Tyler-Marie</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munter</LastName><ForeName>Sadie E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lombardo</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wrin</LastName><ForeName>Terri</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petropoulos</LastName><ForeName>Christos J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Monogram Biosciences, South San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durstenfeld</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsue</LastName><ForeName>Priscilla Y</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Division of Cardiology, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>J Daniel</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenhouse</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeks</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henrich</LastName><ForeName>Timothy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI157875</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AI162249</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HL143961</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI141003</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AI147159</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>J Med Virol. 2023 Nov;95(11):e29216. doi: 10.1002/jmv.29216</RefSource><PMID Version="1">37988251</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Neutralizing Antibodies</Keyword><Keyword MajorTopicYN="N">Post-Acute Sequelae of SARS-CoV-2 infection (PASC)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>MJP reports consulting fees for Gilead Sciences and AstraZeneca, outside the submitted work. TJH receives grant support from Merck and Co. and has consulted for Roche and Regeneron.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>4</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37034660</ArticleId><ArticleId IdType="pmc">PMC10081395</ArticleId><ArticleId IdType="doi">10.1101/2023.03.30.23287923</ArticleId><ArticleId IdType="pii">2023.03.30.23287923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ayoubkhani D., et al., Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ, 2022. 377: p. e069676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Seessle J., et al., Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis, 2022. 74(7): p. 1191&#x2013;1198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., et al., Omicron variants of SARS-CoV-2 and long COVID. Front Immunol, 2022. 13: p. 1061686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9780375</ArticleId><ArticleId IdType="pubmed">36569883</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., et al., Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement. Open Forum Infect Dis, 2022. 9(2): p. ofab640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755302</ArticleId><ArticleId IdType="pubmed">35106317</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Donatelli J., and Henrich T.J., Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res, 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8588584</ArticleId><ArticleId IdType="pubmed">34780969</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J. and Deeks S.G., Early clues regarding the pathogenesis of long-COVID. Trends Immunol, 2022. 43(4): p. 268&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S. and Merad M., Pathological sequelae of long-haul COVID. Nat Immunol, 2022. 23(2): p. 194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D., et al., Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med, 2022. 54(1): p. 1473&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., et al., Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest, 2023. 133(3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., et al., Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 2022. 185(5): p. 881&#x2013;895 e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., et al., Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens, 2021. 10(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z., et al., Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis, 2023. 76(3): p. e487&#x2013;e490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A., et al., Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y), 2022. 3(6): p. 371&#x2013;387 e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., et al., SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. Ann Neurol, 2022. 91(6): p. 772&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9082480</ArticleId><ArticleId IdType="pubmed">35285072</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., et al., Distinguishing features of Long COVID identified through immune profiling. medRxiv, 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjelltveit E.B., et al., Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study. Clin Infect Dis, 2023. 76(3): p. e60&#x2013;e70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384725</ArticleId><ArticleId IdType="pubmed">35959897</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurahashi Y., et al., Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections. Front Immunol, 2022. 13: p. 773652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8907139</ArticleId><ArticleId IdType="pubmed">35281007</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin K., et al., Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv, 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10834368</ArticleId><ArticleId IdType="pubmed">38212464</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruell H., et al., Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022. 55(6): p. 925&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9118976</ArticleId><ArticleId IdType="pubmed">35623355</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., et al., Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep, 2021. 36(6): p. 109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., et al., SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. Sci Adv, 2021. 7(31).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324059</ArticleId><ArticleId IdType="pubmed">34330709</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Abellan J., et al., Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study. J Clin Immunol, 2021. 41(7): p. 1490&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285689</ArticleId><ArticleId IdType="pubmed">34273064</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman J.D., et al., Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19. medRxiv, 2022.</Citation></Reference><Reference><Citation>Sullivan D.J., et al., Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. Nat Commun, 2022. 13(1): p. 6478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9617541</ArticleId><ArticleId IdType="pubmed">36309490</ArticleId></ArticleIdList></Reference><Reference><Citation>Linderman S.L., et al., Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection. J Clin Invest, 2022. 132(23).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711871</ArticleId><ArticleId IdType="pubmed">36256473</ArticleId></ArticleIdList></Reference><Reference><Citation>Odak I., et al., Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. Front Immunol, 2022. 13: p. 863039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8964088</ArticleId><ArticleId IdType="pubmed">35359969</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuh A.J., et al., SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection. Microbiol Spectr, 2022. 10(4): p. e0124722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9430572</ArticleId><ArticleId IdType="pubmed">35856710</ArticleId></ArticleIdList></Reference><Reference><Citation>Fong Y., et al., Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat Commun, 2023. 14(1): p. 331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9851580</ArticleId><ArticleId IdType="pubmed">36658109</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., et al., Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. Sci Rep, 2021. 11(1): p. 23921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8671391</ArticleId><ArticleId IdType="pubmed">34907214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C., et al., Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med, 2023. 29(2): p. 344&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi D., Hu J., and Qian Z., A Lentiviral Pseudotype System to Characterize SARS-CoV-2 Glycoprotein. Methods Mol Biol, 2023. 2610: p. 187&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">36534292</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyseni I., et al., Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays. Viruses, 2020. 12(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7551040</ArticleId><ArticleId IdType="pubmed">32927639</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K.T., et al., Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody. Viruses, 2022. 14(7).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9322699</ArticleId><ArticleId IdType="pubmed">35891540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>